stockrow
Saturday 7 November 2026
Export MIST’s income statement to Excel — free account
Milestone Pharmaceuticals Inc.
MIST Healthcare Biotechnology
Milestone Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 million, up 54.6% from fiscal 2023.
- Revenue
- −62.7%
- EPS
- −5.00%
- Free cash flow
- −80.8%
- Total debt
- +7.19%
Quarter to June 2026, against a year earlier
0.76
0.07
+10.14%
Follow MIST
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | 0.00 | 0.00 |
P/S ratio |
— | — | 24.85 | 35.09 | |
P/FCF ratio |
— | — | 0.00 | 0.00 | |
P/Operating CF |
— | — | (9.66) | (8.18) | |
P/B ratio |
— | — | 4.30 | 10.20 | |
Price to Tangible BV |
— | — | 4.30 | 10.20 | |
EV/Sales |
— | — | 4.65 | 14.05 | |
EV/EBITDA |
— | — | 0.00 | 0.00 | |
EV/Operating CF |
— | — | (0.57) | (1.21) | |
EV/FCF |
— | — | (0.56) | (1.21) | |
Quick Ratio |
7.91 | 7.70 | 8.94 | 7.85 | |
Current Ratio |
8.24 | 8.01 | 9.18 | 8.13 | |
Net Debt/EBITDA |
2.23 | 2.60 | 5.34 | 4.36 | |
Debt/Assets |
64.05% | 50.36% | 30.04% | 32.60% | |
Debt/Equity |
2.74 | 1.37 | 1.61 | 3.25 | |
Asset Turnover |
0.00 | 0.00 | 0.05 | 0.05 | |
Operating CF/Net income |
0.82 | 0.73 | 0.62 | 0.79 | |
Capex/Depreciation |
(0.08) | (8.32) | (0.80) | (0.46) | |
Interest Coverage |
(12.23) | (17.52) | (5.72) | (5.42) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 1,365.97% | 627.73% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 2,026.89% | 4,051.52% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 538.66% | 239.36% | |
Graham Net Nets |
— | — | 0.22 | 0.09 | |
Graham Number |
— | — | 0.00 | 0.00 | |
Earnings Yield |
— | — | (57.14%) | (51.49%) | |
Free Cash Flow Yield |
— | — | (33.21%) | (33.17%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.10) | (0.15) | (0.12) | (0.16) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.10) | (0.16) | (0.12) | (0.16) | |
Cash per Share |
0.86 | 1.26 | 1.41 | 1.23 | |
Shareholders Equity per Share |
0.21 | 0.50 | 0.28 | 0.13 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.21 | 0.50 | 0.28 | 0.13 | |
Free Cash Flow |
(9.75) | (13.06) | (16.10) | (22.74) | |
Working Capital |
76.15 | 97.94 | 171.31 | 158.14 | |
Capital Expenditures |
0.00 | (0.28) | (0.04) | (0.03) | |
Net Current Asset Value |
19.42 | 40.13 | 34.57 | 16.92 | |
EV/EBIT |
— | — | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.19 | 0.05 | |
Price to Operating Income |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.96 | 1.57 | 2.10 | 2.19 | |
Average Payables |
7.36 | 6.60 | 11.22 | 8.61 | |
Average Assets |
85.23 | 94.53 | 127.81 | 114.52 | |
Average Common Equity |
22.26 | 27.46 | 14.96 | 0.24 |
Columns are period end dates